Actithera
PrivateLast Round
Series A
Jul 9, 2025
Total Funding Raised
$80.8M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Actithera operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in July 2025.
Actithera is a biotechnology company that develops radiopharmaceutical and next-generation radioligand therapies for cancer treatment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Actithera Comparables
Compare Actithera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TwoStep Therapeutics | 88% | |
| RatioTX | 88% | |
| ARTBIO | 82% |
For institutional investors. Book with your work email.
Actithera Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Actithera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series A |
| Innovestor | Series A |
| M Ventures | Seed, Series A |
| 4BIO Capital | Series A |
| Investinor | Series A |
| Bioqube Ventures | Series A |
| Citadel | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 24, 2026
Grew 17% QoQ, from 29 to 34 employees.
- Jul 28, 2026
Grew 18% QoQ, from 28 to 33 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 10, 2026
Actithera appoints Briggs Morrison as Chair of the Board on Sep 10th '26 in Norway and Massachusetts, strengthening its leadership team as it advances into clinical development.
- hiresSep 10, 2026
On Sep 10th '26, Actithera appoints John Crowley as an independent director, adding strategic, financial and capital markets leadership as the company advances toward clinical development in Norway and Massachusetts.
- hiresSep 10, 2026
Actithera appoints Steven Kelly as Chief Executive Officer and a member of its Board of Directors on Sep 10th '26 in Norway and the United States, where he leads the company through clinical development and continued pipeline expansion.
For institutional investors. Book with your work email.
Actithera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Actithera's valuation, stock price, and market status.
Is Actithera a public or private company?
Actithera is a private company.
What is the current stock price of Actithera?
Actithera is a private company, so its shares have no public market price. Caplight tracks Actithera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Actithera worth (valuation)?
Valuation information for Actithera is not publicly available.
Can I buy Actithera stock?
Actithera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Actithera's last funding round?
Actithera's most recent funding round was Series A on July 9, 2025.
Who are the main investors in Actithera?
Key investors in Actithera include M Ventures, 4BIO Capital, Sofinnova Partners, Hadean Ventures.
Will Actithera IPO soon?
No public IPO plans have been announced for Actithera.
How can I track Actithera secondary market activity?
Caplight tracks bids, offers, and trades in Actithera's shares on secondary markets.